$ANTB...Annouunces Appointment Of Dr. Hoyoung Huh As Chairman Of Scientific Advisory Board And Business Development
inShare
1/9/2015 9:08:22 AM
LOUISVILLE, CO and MENLO PARK, CA--(Marketwired - January 08, 2015) - AntriaBio, Inc. ("AntriaBio or the "Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board.
Dr. Huh stated, "AntriaBio has tremendous potential to transform the therapeutic regimen in diabetes and significantly improve the standard of care in other disease states. The Company has matured and achieved critical milestones over the past 12 months, including compelling preclinical studies in multiple animal species for its lead product candidate, AB101."
In his expanded role, Dr. Huh will partner with his long-time colleague, Nevan Elam, the Company's Chairman and Chief Executive Officer, as well as the Chief Scientific Officer, Dr. Sankaram Mantripragada.
"We are very excited to have Hoyoung join us in a more direct capacity as we seek to broaden AntriaBio's vision and strategy. Hoyoung is a widely respected visionary and entrepreneur in our industry. His insights and direction will be invaluable as we head into the next phase of our growth," noted Mr. Elam.
About AntriaBio, Inc. AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $10 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit: www.antriabio.com.
News 
Market Data 
Discover 
AI
